Page last updated: 2024-11-05

ticlopidine and Deep Vein Thrombosis

ticlopidine has been researched along with Deep Vein Thrombosis in 38 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Research Excerpts

ExcerptRelevanceReference
"Warfarin treatment within 12 months achieved significantly higher rates of complete recanalization than aspirin or clopidogrel in patients with PVT (54."5.48Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors, Warfarin Efficacy, and Clinical Outcomes. ( Li, YH; Wu, HM; Xu, Y; Yang, J; Yang, LH; Yue-Meng, W, 2018)
"Stasis ulcers are commonly the result of chronic venous insufficiency."5.31Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report. ( Bick, RL; Scott, RG, 2001)
"Based on the established fact that anticoagulation with warfarin is superior to antiplatelet agents in the prevention of thromboembolic events in atrial fibrillation (AF), we propose that, in contrast to atherothrombotic disorders, the risk of developing a stroke or thromboembolic event in AF is more likely to be affected by the coagulation pathway than by platelet activity."4.82Atrial fibrillation: should we target platelets or the coagulation pathway? ( Lip, GY; Tan, KT, 2003)
"To compare venous thrombosis rates among animals treated with aspirin, clopidogrel bisulfate, and ketorolac tromethamine using an anastomotic "tuck" model."3.77Effects of antithrombogenic agents on microvenous anastomoses in a rat model. ( Harsha, WJ; Hayden, RE; Kau, RL; Kim, N, 2011)
"The antithrombotic effect of Danggui and Honghua, herbs commonly used in Traditional Chinese medicine to treat the syndrome corresponding to vascular thrombosis, and their potential interactions with clopidogrel were investigated."3.76Antithrombotic effects of Danggui, Honghua and potential drug interaction with clopidogrel. ( Li, Y; Wang, N, 2010)
"Thrombosis is of greater overall clinical importance in terms of morbidity and mortality than all of the hemorrhagic disorders combined."2.41Antithrombotic agents: implications in dentistry. ( Henry, RG; Little, JW; McIntosh, BA; Miller, CS, 2002)
"Warfarin treatment within 12 months achieved significantly higher rates of complete recanalization than aspirin or clopidogrel in patients with PVT (54."1.48Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors, Warfarin Efficacy, and Clinical Outcomes. ( Li, YH; Wu, HM; Xu, Y; Yang, J; Yang, LH; Yue-Meng, W, 2018)
"Thulium VapoEnucleation of the prostate seems to be a safe and efficacious procedure for the treatment of symptomatic BPO in patients at high cardiopulmonary risk on OA."1.40Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. ( Bach, T; Brüning, M; Gabuev, A; Gross, AJ; Herrmann, TR; Netsch, C; Stoehrer, M, 2014)
"Intrahepatic hemorrhage is a very rare complication of warfarin, and our patient experienced intrahepatic and subgaleal hemorrhage although she did not have any risk factors for bleeding or instability of the international normalized ratio control."1.39Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy. ( Baek, YH; Cho, DS; Chung, WT; Han, SY; Kang, SH; Lee, SW; Park, IC, 2013)
"Clinically symptomatic deep venous thrombosis was detected in association with four (0."1.34Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. ( Boutary, M; Dorr, LD; Gendelman, V; Long, WT; Maheshwari, AV; Wan, Z, 2007)
"Early administration of a combined regimen of clopidogrel and aspirin following off-pump CABG is safe and is associated with a relatively low incidence of major adverse cardiac events, bleeding, PE, and DVT."1.32A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting. ( Benhameid, O; Endo, M; Shennib, H, 2003)
"Stasis ulcers are commonly the result of chronic venous insufficiency."1.31Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report. ( Bick, RL; Scott, RG, 2001)

Research

Studies (38)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (2.63)18.2507
2000's22 (57.89)29.6817
2010's15 (39.47)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wan, YM1
Li, YH2
Wu, HM2
Xu, ZY1
Xu, Y2
Yang, LH2
Wu, XN1
Yang, JH1
Belcaro, G1
Dugall, M1
Hu, S1
Feragalli, B1
Cotellese, R1
Ledda, A1
Corsi, M1
Ricci, A1
Ippolito, E1
Errichi, BM1
Cornelli, U1
Cesarone, MR1
Hosoi, M1
Cooley, BC2
Herrera, AJ1
Netsch, C1
Stoehrer, M1
Brüning, M1
Gabuev, A1
Bach, T1
Herrmann, TR1
Gross, AJ1
Park, IC1
Baek, YH1
Han, SY1
Lee, SW2
Chung, WT1
Kang, SH1
Cho, DS1
Lawall, H1
Oberacker, R1
Zemmrich, C1
Bramlage, P1
Diehm, C1
Schellong, SM1
Gavrilenko, AV1
Voronov, DA1
Damanti, S1
Artoni, A1
Lucchi, T1
Mannucci, PM1
Mari, D1
Bergamaschini, L1
Windecker, S1
Tijssen, J1
Giustino, G1
Guimarães, AH1
Mehran, R1
Valgimigli, M1
Vranckx, P1
Welsh, RC1
Baber, U1
van Es, GA1
Wildgoose, P1
Volkl, AA1
Zazula, A1
Thomitzek, K1
Hemmrich, M1
Dangas, GD1
Yue-Meng, W1
Yang, J1
Lijnen, HR1
Helsen, S1
Hoylaerts, MF1
Li, Y1
Wang, N1
Scacciatella, P1
Butera, G1
Amato, G1
Tomassini, F1
Giorgi, M1
Marra, S1
Naik, A1
Mian, T1
Abraham, A1
Rajput, V1
Harsha, WJ1
Kau, RL1
Kim, N1
Hayden, RE1
Alam, M1
Goldberg, LH1
Hankey, GJ1
Eikelboom, JW1
Jessup, DB1
Coletti, AT1
Muhlestein, JB1
Barry, WH1
Shean, FC1
Whisenant, BK1
Igaki, N1
Matsuda, T1
Yatani, H1
Kawaguchi, T1
Kida, A1
Yanase, K1
Moriguchi, R1
Sakai, M1
Tamada, F1
Goto, T1
Shennib, H1
Endo, M1
Benhameid, O1
Di Micco, B1
Di Micco, G1
Niglio, A1
Romano, M1
Di Micco, P1
Tan, KT1
Lip, GY1
Cattaneo, M1
Sick, PB1
Brosteanu, O1
Ulrich, M1
Thiele, H1
Niebauer, J1
Busch, I1
Schuler, G1
Meyer Samama, M1
Hitos, K1
Fletcher, JP1
Helft, G1
Gilard, M1
Le Feuvre, C1
Zaman, AG1
Zimarino, M1
Renda, G1
De Caterina, R1
Dorr, LD1
Gendelman, V1
Maheshwari, AV1
Boutary, M1
Wan, Z1
Long, WT1
McBane, RD1
Leadley, RJ1
Baxi, SM1
Karnicki, K1
Wysokinski, W1
Katz, MG1
Shimonov, M1
Elias, S1
Ben Eli, M1
Hauptman, E1
Sasson, L1
Landolfi, R1
Di Gennaro, L1
Morishita, K1
Iwamoto, M1
Frangos, SG1
Chen, AH1
Sumpio, B1
Bick, RL1
Scott, RG1
Tufano, A1
Cerbone, AM1
Di Minno, G1
Little, JW1
Miller, CS1
Henry, RG1
McIntosh, BA1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145]Phase 440 participants (Actual)Interventional2020-06-23Completed
Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203]Phase 31,653 participants (Actual)Interventional2015-12-16Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator)
[NCT00000614]Phase 30 participants Interventional1998-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Cardiovascular Death or Thromboembolic Event

Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)83
Antiplatelet68

Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds

Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)148
Antiplatelet85

Number of Participants With Death or First Thromboembolic Event (DTE)

Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)68
Antiplatelet63

Number of Participants With Death or First Thromboembolic Event (DTE)

Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)105
Antiplatelet78

Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds

ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)49
Antiplatelet30

Number of Participants With Net-clinical Benefit

The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)137
Antiplatelet100

Number of Participants With Primary Bleeding Event (PBE)

PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)46
Antiplatelet31

Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds

Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)42
Antiplatelet24

Reviews

8 reviews available for ticlopidine and Deep Vein Thrombosis

ArticleYear
Economy class syndrome complicated by stroke: a rare condition due to paradoxical embolism--a case report and review of the literature.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2011, Volume: 12, Issue:8

    Topics: Aircraft; Anticoagulants; Aspirin; Clopidogrel; Echocardiography; Embolism, Paradoxical; Foramen Ova

2011
Atrial fibrillation: should we target platelets or the coagulation pathway?
    Cardiac electrophysiology review, 2003, Volume: 7, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Assessment;

2003
Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance.
    Arteriosclerosis, thrombosis, and vascular biology, 2004, Volume: 24, Issue:11

    Topics: Aspirin; Clopidogrel; Drug Resistance; Humans; Ticlopidine; Treatment Failure; Treatment Outcome; Ve

2004
[The new antithrombotic agents].
    Presse medicale (Paris, France : 1983), 2005, Oct-22, Volume: 34, Issue:18

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylami

2005
Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation.
    Nature clinical practice. Cardiovascular medicine, 2006, Volume: 3, Issue:12

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Admi

2006
Vascular drugs in the new millennium.
    Journal of the American College of Surgeons, 2000, Volume: 191, Issue:1

    Topics: Abciximab; Animals; Anistreplase; Antibodies, Monoclonal; Anticoagulants; Aspirin; Chondroitin Sulfa

2000
The use of antithrombotic drugs in older people.
    Minerva medica, 2002, Volume: 93, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myo

2002
Antithrombotic agents: implications in dentistry.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2002, Volume: 93, Issue:5

    Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Dental Care; Drug Interactions; Embol

2002

Trials

3 trials available for ticlopidine and Deep Vein Thrombosis

ArticleYear
[Possibilities and results of using clopidogrel (Listab) in comprehensive treatment of patients with crural deep veins thrombosis].
    Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2015, Volume: 21, Issue:1

    Topics: Adult; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leg;

2015
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    American heart journal, 2017, Volume: 184

    Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy,

2017
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    American heart journal, 2017, Volume: 184

    Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy,

2017
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    American heart journal, 2017, Volume: 184

    Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy,

2017
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    American heart journal, 2017, Volume: 184

    Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy,

2017
Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
    American heart journal, 2005, Volume: 149, Issue:4

    Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biocompatibl

2005

Other Studies

27 other studies available for ticlopidine and Deep Vein Thrombosis

ArticleYear
Portal vein thrombosis before and after transjugular intrahepatic portosystemic shunt placement: An observational study (STROBE compliant).
    Medicine, 2017, Volume: 96, Issue:45

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Female; Humans; Leukocyte Coun

2017
Prevention of recurrent venous thrombosis and post-thrombotic syndrome.
    Minerva cardioangiologica, 2018, Volume: 66, Issue:3

    Topics: Aspirin; Drug Therapy, Combination; Female; Fibrinolytic Agents; Flavonoids; Glycosaminoglycans; Hum

2018
Cross-modulatory effects of clopidogrel and heparin on platelet and fibrin incorporation in thrombosis.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2013, Volume: 24, Issue:6

    Topics: Animals; Anticoagulants; Blood Coagulation; Blood Platelets; Clopidogrel; Disease Models, Animal; Dr

2013
Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy.
    World journal of urology, 2014, Volume: 32, Issue:1

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Hemorrhage; Humans; Incidence; Mal

2014
Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy.
    World journal of gastroenterology, 2013, Oct-14, Volume: 19, Issue:38

    Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Chemical and Drug Induced Liver Injury; Clopi

2013
Prevalence of deep vein thrombosis in acutely admitted ambulatory non-surgical intensive care unit patients.
    BMC research notes, 2014, Jul-05, Volume: 7

    Topics: Aged; Aged, 80 and over; Anticoagulants; APACHE; Aspirin; Clopidogrel; Female; Fibrin Fibrinogen Deg

2014
A thrombotic storm.
    Internal and emergency medicine, 2017, Volume: 12, Issue:1

    Topics: Aged; Alprazolam; Amines; Amputation, Surgical; Atorvastatin; Cyclohexanecarboxylic Acids; Female; G

2017
Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors, Warfarin Efficacy, and Clinical Outcomes.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018, Volume: 24, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Elective Surgical Procedures; Female; Fibrosis

2018
Antithrombotic effect of clopidogrel in a vena cava thrombosis model in obese mice.
    Thrombosis research, 2009, Volume: 123, Issue:5

    Topics: Animals; Clopidogrel; Dietary Fats; Disease Models, Animal; Fibrinolytic Agents; Mice; Mice, Obese;

2009
Antithrombotic effects of Danggui, Honghua and potential drug interaction with clopidogrel.
    Journal of ethnopharmacology, 2010, Apr-21, Volume: 128, Issue:3

    Topics: Animals; Bleeding Time; Carthamus tinctorius; Clopidogrel; Drug Interactions; Drugs, Chinese Herbal;

2010
Iliac vein compression syndrome: an underdiagnosed cause of lower extremity deep venous thrombosis.
    Journal of hospital medicine, 2010, Volume: 5, Issue:7

    Topics: Anticoagulants; Clopidogrel; Constriction, Pathologic; Heparin; Humans; Iliac Vein; Lower Extremity;

2010
Effects of antithrombogenic agents on microvenous anastomoses in a rat model.
    Archives of otolaryngology--head & neck surgery, 2011, Volume: 137, Issue:2

    Topics: Anastomosis, Surgical; Animals; Aspirin; Clopidogrel; Femoral Vein; Ketorolac Tromethamine; Microcir

2011
Collagen-induced thrombosis in murine arteries and veins.
    Thrombosis research, 2013, Volume: 131, Issue:1

    Topics: Animals; Arterial Occlusive Diseases; Blood Coagulation; Blood Platelets; Carotid Arteries; Clopidog

2013
Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2002, Volume: 28, Issue:11

    Topics: Aged; Anticoagulants; Aspirin; Carcinoma, Basal Cell; Clopidogrel; Drug Administration Schedule; Fem

2002
Antiplatelet drugs.
    The Medical journal of Australia, 2003, Jun-02, Volume: 178, Issue:11

    Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein G

2003
Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2003, Volume: 60, Issue:2

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Atrial Fibrillation; Cardia

2003
Deep venous thrombosis, myocardial infarction, and occlusion of vascular access associated with heparin-induced thrombocytopenia in a diabetic hemodialysis patient.
    Clinical and experimental nephrology, 2003, Volume: 7, Issue:4

    Topics: Anticoagulants; Catheters, Indwelling; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fi

2003
A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting.
    The heart surgery forum, 2003, Volume: 6, Issue:5

    Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Feasibility

2003
Proximal deep venous thrombosis occurring after sudden clopidogrel suspension.
    European journal of clinical pharmacology, 2004, Volume: 60, Issue:1

    Topics: Aged; Atrial Fibrillation; Clopidogrel; Humans; Male; Platelet Aggregation Inhibitors; Prognosis; Su

2004
Venous thromboembolism and fractured neck of femur.
    Thrombosis and haemostasis, 2005, Volume: 94, Issue:5

    Topics: Aged; Aged, 80 and over; Anesthesia; Anticoagulants; Aspirin; Blood Loss, Surgical; Blood Transfusio

2005
Triple antithrombotic therapy with aspirin, clopidogrel and warfarin--a persisting dilemma.
    Internal and emergency medicine, 2007, Volume: 2, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Fibrinoly

2007
Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment.
    The Journal of bone and joint surgery. American volume, 2007, Volume: 89, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac

2007
Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct Factor Xa inhibitor, compared with antiplatelet agents in pigs.
    Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:3

    Topics: Administration, Oral; Angioplasty; Animals; Antithrombin III; Aspirin; Clopidogrel; Constriction, Pa

2008
Portal vein thrombosis associated with coronary artery bypass surgery.
    The Journal of cardiovascular surgery, 2008, Volume: 49, Issue:1

    Topics: Aged; Aspirin; Bacteremia; Clopidogrel; Coagulase; Coronary Artery Bypass; Esophageal and Gastric Va

2008
Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
    Haematologica, 2008, Volume: 93, Issue:3

    Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans;

2008
Synergistic antithrombotic effects of argatroban and ticlopidine in the rat venous thrombosis model.
    Thrombosis research, 1998, Dec-15, Volume: 92, Issue:6

    Topics: Animals; Anticoagulants; Antithrombins; Arginine; Drug Synergism; Male; Pipecolic Acids; Rats; Rats,

1998
Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2001, Volume: 7, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antiphospholipid Syndrome; Clopidogrel; Dalteparin;

2001